




Instance: composition-en-1d09f2cdb23b1c4baeb1be5a4de77a38
InstanceOf: CompositionUvEpi
Title: "Composition for sibnayal Package Leaflet"
Description:  "Composition for sibnayal Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/20/1517/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp1d09f2cdb23b1c4baeb1be5a4de77a38)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - sibnayal"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Sibnayal is and what it is used for  </li>
<li>What you need to know before you take Sibnayal  </li>
<li>How to take Sibnayal </li>
<li>Possible side effects  </li>
<li>How to store Sibnayal </li>
<li>Contents of the pack and other information </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What sibnayal is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What sibnayal is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sibnayal contains two active substances, potassium citrate and potassium hydrogen carbonate (also 
known as potassium bicarbonate).  </p>
<p>Sibnayal is an alkalising medicine that is used to control blood acidity caused by a kidney disease 
called distal renal tubular acidosis (dRTA).  </p>
<p>Sibnayal will help reduce the effect of dRTA on your everyday life. </p>
<p>Sibnayal is used in adults, adolescents and children above 1 year. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take sibnayal"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take sibnayal"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Sibnayal if:</p>
<ul>
<li>you are allergic to potassium citrate or potassium bicarbonate or any of the other ingredients of 
this medicine (listed in section 6), </li>
<li>you have a severe kidney disease or kidney failure, </li>
<li>you have a high level of potassium in your blood (hyperkalaemia). </li>
</ul>
<p>Warnings and precautions  </p>
<p>Talk to your doctor before taking Sibnayal if:</p>
<ul>
<li>you have a disease or you take a medicine that can increase your blood potassium (see below  Other 
medicines and Sibnayal ), </li>
<li>you frequently have gastro-intestinal symptoms such as bloating, diarrhoea, nausea, vomiting, </li>
<li>you have chronic kidney disease. </li>
</ul>
<p>Sibnayal prolonged-release granules are designed to release the active substances slowly after taking the 
granules. You may see remains of the granules in your stools. This is normal and does not reduce the 
effectiveness of the medicine. </p>
<p>If you vomit within two hours after intake, you should take another dose. </p>
<p>You will need regular appointments with your doctor. From time to time, your doctor may need to do 
blood, urine or heart tests, to adjust the dose of Sibnayal. Your doctor will regularly check your kidney 
function if you are elderly and/or have worsening kidney function.  </p>
<p>Children </p>
<p>Do not give this medicine to children below 1 year of age because of the risk of choking.  </p>
<p>Other medicines and Sibnayal </p>
<p>Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. </p>
<p>Some medicines may affect how Sibnayal works or make side effects more likely. These include:</p>
<ul>
<li>
<p>any medicine that increases the level of potassium in your blood such as:</p>
</li>
<li>
<p>angiotensin-converting enzyme (ACE) inhibitors (used to treat high blood pressure, heart 
disease and kidney disease in patients suffering from type 1 diabetes), </p>
</li>
<li>potassium-sparing diuretics (used to treat high blood pressure, fluid build-up in tissue 
(oedema) and heart conditions), </li>
<li>potassium supplements (used to prevent or treat low potassium levels in the blood), </li>
<li>ciclosporin (used to prevent or treat transplant rejection), </li>
<li>heparin sodium (used to prevent or delay blood clotting), </li>
<li>nonsteroidal anti-inflammatory drugs (NSAIDs) (used to reduce fever, pain and 
inflammation), </li>
<li>
<p>any medicine that may be affected by a disturbance in the level of potassium in your blood such 
as:</p>
</li>
<li>
<p>digitalis glycosides (such as digoxin, used to treat heart failure and certain heart rhythm 
disorders), </p>
</li>
<li>corticosteroids (used to treat inflammation), </li>
<li>
<p>any other medicine that could cause heart rhythm disorders such as:</p>
</li>
<li>
<p>amiodarone and quinidine (used to control cardiac rhythm), </p>
</li>
<li>chlorpromazine (used to treat certain mental illnesses), </li>
<li>cisapride (used to treat heartburn), </li>
<li>sparfloxacin (used to treat certain bacterial infections). </li>
</ul>
<p>Some medicines may be affected by increased urine pH in relation with Sibnayal treatment such as :</p>
<ul>
<li>salicylates (used to treat pain and inflammation   aspirin-like medicines), </li>
<li>tetracyclines (used to treat certain bacterial infections), </li>
<li>barbiturates (sleep inducing medicines).  </li>
</ul>
<p>Sibnayal with food, drink and alcohol </p>
<p>Do not mix Sibnayal with hot food or hot liquids. <br />
Do not drink alcohol while you are taking Sibnayal.  </p>
<p>Pregnancy, breast-feeding and fertility </p>
<p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine.  </p>
<p>Driving and using machines </p>
<p>Sibnayal is not likely to affect your ability to drive or use machines. </p>
<p>Sibnayal contains potassium </p>
<p>Sibnayal 8 mEq contains 308 mg of potassium per sachet. This is to be taken into consideration if you 
have a reduced kidney function or if you are on a controlled potassium diet. </p>
<p>Sibnayal 24 mEq contains 924 mg of potassium per sachet. This is to be taken into consideration if you 
have a reduced kidney function or if you are on a controlled potassium diet. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take sibnayal"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take sibnayal"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if 
you are not sure. </p>
<p>The amount of Sibnayal that people have to take depends on their age, weight and condition. Your 
doctor will tell you exactly the dose of Sibnayal to take. This will always be one or more whole 
sachets. </p>
<p>Your doctor may need to adjust your dose of Sibnayal. </p>
<p>The use of this medicine requires medical supervision.  </p>
<p>Dosage </p>
<p>The dose is adjusted by the doctor according to the level of bicarbonate in your blood. </p>
<p>How to use </p>
<p>Sibnayal is for oral use (to be taken by mouth). 
If you are not sure of how to use Sibnayal, contact your doctor or pharmacist.  </p>
<ol>
<li>
<p>Hold the sachet vertically with your fingers above the dotted line. Shake it from side to side to ensure 
the contents move to the bottom of the sachet. </p>
</li>
<li>
<p>Cut the sachet along the dotted line, using scissors if necessary. </p>
</li>
<li>
<p>Place all or part of the sachet contents directly into your mouth on your tongue. </p>
</li>
<li>
<p>Swallow the granules immediately with a large glass of water. Do not chew or crush the granules. 
Repeat steps 1 to 4 as required until you have taken the full dose.  </p>
</li>
</ol>
<p>For patients who are unable to swallow granules </p>
<ol>
<li>
<p>Mix Sibnayal with small amounts of soft and cold food (e.g. fruit puree or yoghurt) directly on the 
spoon. You must swallow the soft food mixture immediately. Do not store the mixture for use later. </p>
</li>
<li>
<p>Place the mixture directly into the mouth and swallow it without chewing. Make sure that Sibnayal 
does not remain in the mouth. Repeat steps 1 and 2 as required until the full dose has been taken.  </p>
</li>
</ol>
<p>Do not mix the granules with liquid before taking them. </p>
<p>When to take Sibnayal </p>
<p>Take Sibnayal in the morning and in the evening, during a meal. You must leave an interval of about hours in between each dose to cover the whole night-and-day period. </p>
<p>Dose adjustment </p>
<p>Dose increases/decreases should be gradual, taking place over a few weeks. Your doctor will adjust the 
dose according to your condition. The usual recommended dose is 4 to 6 whole sachets of 24 mEq 
each day. </p>
<p>Please consult your doctor in the event of any side effects, as he / she may have to adjust the dose of 
this medicine.  </p>
<p>Switch from another alkalising medicine </p>
<p>If you are switching from another alkalising medicines to Sibnayal, your doctor should closely 
supervise the switchover.  </p>
<p>If you take more Sibnayal than you should </p>
<p>Talk to your doctor or pharmacist if you have taken more Sibnayal than you should have. 
You may feel nauseous, need to vomit and have diarrhoea. 
If you have taken a large amount of Sibnayal, you may feel weak or get unexplained tightness of the 
muscles, spasms (muscular contraction), abnormal tingling or burning sensations, pins and needles or 
numbness, mental confusion or an abnormal heart rate.   </p>
<p>If you forget to take Sibnayal </p>
<p>Do not take a double dose to make up for a forgotten dose. Take it as soon as you remember. However, 
if your next dose is in less than six hours, skip the missed dose. Do not take more than two doses a 
day.  </p>
<p>Talk to your doctor if you forget to take one or more doses. </p>
<p>If you stop taking Sibnayal </p>
<p>This medicine is for long-term use. It will only be effective as long as you are using it. 
Do not stop unless your doctor tells you to, even if you feel better, as your disease may get worse. If 
you want to stop treatment, first talk to your doctor. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Very common side effects (which may affect more than 1 in 10 people) 
- abdominal pain (belly pain) </p>
<p>Common side effects (which may affect up to 1 in 10 people) 
- upper abdominal pain (upper belly pain), 
- gastrointestinal pain and disorders (stomach and intestinal pain and disorders), 
- dyspepsia (poor digestion), 
- vomiting,<br />
- diarrhoea 
- feeling sick (nausea) when starting treatment. </p>
<p>Reporting of side effects </p>
<p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store sibnayal"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store sibnayal"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the sachet and the carton after EXP. 
The expiry date refers to the last day of that month. </p>
<p>Do not store above 25 C. </p>
<p>After opening a sachet, discard any unused content. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Sibnayal contains </p>
<p>The active substances are potassium citrate and potassium hydrogen carbonate (also known as potassium 
bicarbonate). </p>
<p>Each sachet of Sibnayal 8 mEq contains 282 mg of potassium citrate and 527 mg of potassium 
hydrogen carbonate. </p>
<p>Each sachet of Sibnayal 24 mEq contains 847 mg of potassium citrate and 1,582 mg of potassium 
hydrogen carbonate. </p>
<p>The other ingredients are hypromellose (E464), microcrystalline cellulose (E460 (i)), glycerol 
dibehenate, magnesium stearate (E470b), silica colloidal anhydrous, magnesium oxide heavy (E530), 
ethylcellulose (E462), chlorophyllin (E140 (ii)), talc. </p>
<p>What Sibnayal looks like and contents of the pack </p>
<p>Sibnayal is a mixture of green and white prolonged-released granules supplied in sachets. 
Cartons contain 60 sachets. </p>
<p>Sibnayal is available in multipacks comprising 2, 3, 4, 5 and 6 cartons, each containing 60 sachets. 
Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder </p>
<p>ADVICENNE<br />
262 rue du Faubourg Saint Honor <br />
75008 Paris 
France </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien - Luxembourg/Luxemburg - Nederland 
TwinPharma BV 
Trasmolenlaan 5 
3447 GZ Woerden 
Nederland 
T l/Tel: +31 348 71 24 e-mail: info@twinpharma.com </p>
<p>Italia 
SPA Societ  Prodotti Antibiotici S.p.A. 
Tel: +39 02 891<br />
ExCEEd Orphan s.r.o. 
Bucharova 2657/12, Prague 5, 158 Czech republic 
Te .: +359 888 918 pv.global@exceedorphan.com </p>
<p>Magyarorsz g 
ExCEEd Orphan s.r.o. 
Bucharova 2657/12, Prague 5, 158 Czech republic 
Tel.: +36 20 399 4pv.global@exceedorphan.com 
 esk  republika 
ExCEEd Orphan s.r.o. 
Bucharova 2657/12, Prague 5, 158 Czech republic 
Tel: +420 608 076 pv.global@exceedorphan.com </p>
<p>Polska 
ExCEEd Orphan s.r.o. 
Bucharova 2657/12, Prague 5, 158 Czech republic 
Tel.: +48 502 188 pv.global@exceedorphan.com 
Danmark - Norge - Suomi/Finland - Sverige 
Frostpharma AB 
Berga Backe 2 
18253 Danderyd, Sverige<br />
Tlf/Puh/Tel: + 46 8 243regulatory@frostpharma.com </p>
<p>Portugal 
Prospa   Laborat rios Farmac uticos, S.A. 
Tel: +351 214171Deutschland - Eesti       France <br />
Ireland    sland       Latvija - Lietuva - Malta    sterreich - United Kingdom 
(Northern Ireland) 
ADVICENNE 
262 rue du Faubourg Saint Honor <br />
75008 Paris, France 
Tel : + 33 1 85 73 36 Rom nia 
ExCEEd Orphan s.r.o. 
Bucharova 2657/12, Prague 5, 158 Czech republic 
Tel: +40 744 366 pv.global@exceedorphan.com 
Espa a 
SPA farma Ib rica<br />
Tel: + 34 622 273 Slovenija 
ExCEEd Orphan s.r.o. 
Bucharova 2657/12, Prague 5, 158 Czech republic 
Tel: +386 30 210 pv.global@exceedorphan.com </p>
<p>Hrvatska 
ExCEEd Orphan Distribution d.o.o. 
Savska cesta 32, Zagreb, 100 Croatia 
Tel: +385 99 320 0pv.global@exceedorphan.com<br />
Slovensk  republika 
ExCEEd Orphan s.r.o. 
Bucharova 2657/12, Prague 5, 158 Czech republic 
Tel: +420 608 076 pv.global@exceedorphan.com </p>
<p>Manufacturer </p>
<p>ELAIAPHARM 
2881 route des Cr tes 
ZI les Bouillides Sophia Antipolis<br />
06560 Valbonne 
France </p>
<p>This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p> </div>"""      



Instance: composition-da-1d09f2cdb23b1c4baeb1be5a4de77a38
InstanceOf: CompositionUvEpi
Title: "Composition for sibnayal Package Leaflet"
Description:  "Composition for sibnayal Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/20/1517/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp1d09f2cdb23b1c4baeb1be5a4de77a38)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - sibnayal"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. INDLÆGSSEDDEL"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. INDLÆGSSEDDEL"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Indlægsseddel: Information til brugeren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Indlægsseddel: Information til brugeren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "Oversigt over indlægssedlen"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Oversigt over indlægssedlen"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Sibnayal </li>
<li>Sådan skal du tage Sibnayal </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. Virkning og anvendelse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. Virkning og anvendelse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sibnayal indeholder to aktive stoffer, nemlig kaliumcitrat og kaliumhydrogencarbonat (også kaldet 
kaliumbicarbonat). </p>
<p>Sibnayal er et alkaliserende lægemiddel, der anvendes til at behandle øget blodsurhed forårsaget af en 
nyresygdom kaldet distal renal tubulær acidose (dRTA). </p>
<p>Sibnayal vil være med til at mindske dRTA's indvirkning på din dagligdag. </p>
<p>Sibnayal anvendes hos voksne, unge og børn over 1 år. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. Det skal du vide, før du begynder at tage  sibnayal"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. Det skal du vide, før du begynder at tage  sibnayal"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Sibnayal:</p>
<ul>
<li>hvis du er allergisk over for kaliumcitrat eller kaliumhydrogencarbonat eller et af de øvrige 
indholdsstoffer i dette lægemiddel (angivet i pkt. 6) </li>
<li>hvis du har en alvorlig nyresygdom eller nyresvigt </li>
<li>hvis du har forhøjet kaliumindhold i blodet (hyperkaliæmi). </li>
</ul>
<p>Advarsler og forsigtighedsregler </p>
<p>Kontakt lægen, før du tager Sibnayal:</p>
<ul>
<li>hvis du har en sygdom eller tager et lægemiddel, der kan øge indholdet af kalium i dit blod (se "Brug 
af anden medicin sammen med Sibnayal" nedenfor) </li>
<li>hvis du ofte har gastrointestinale symptomer såsom oppustethed, diarré, kvalme, opkastning </li>
<li>hvis du lider af en kronisk nyresygdom. </li>
</ul>
<p>Sibnayal, depotgranulat, er beregnet til at frigive de aktive stoffer langsomt efter indtagelse. Du kan 
muligvis se rester af granulatet i din afføring. Dette er normalt og nedsætter ikke lægemidlets virkning. </p>
<p>Hvis du kaster op inden for to timer efter at have indtaget lægemidlet, bør du tage endnu en dosis. </p>
<p>Du er nødt til regelmæssigt at se din læge. Det kan sommetider være nødvendigt, at din læge tager 
blod- eller urinprøver eller tester dit hjerte for at justere dosis af Sibnayal. Din læge vil regelmæssigt 
kontrollere din nyrefunktion, hvis du er ældre og/eller har forværret nyrefunktion. </p>
<p>Børn </p>
<p>Giv ikke dette lægemiddel til børn under 1 år, da der er risiko for kvælning. </p>
<p>Brug af anden medicin sammen med Sibnayal </p>
<p>Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget 
anden medicin eller planlægger at tage anden medicin. </p>
<p>Nogle lægemidler kan påvirke måden, Sibnayal virker på, eller øge sandsynligheden for bivirkninger. 
Disse omfatter:</p>
<ul>
<li>
<p>lægemidler, der øger kaliumindholdet i blodet, såsom:</p>
</li>
<li>
<p>angiotensinkonvertasehæmmere (ACE-hæmmere) (anvendes til at behandle forhøjet 
blodtryk, hjertesygdom og nyresygdom hos patienter med type 1-diabetes) </p>
</li>
<li>kaliumbesparende diuretika (anvendes til at behandle forhøjet blodtryk, ophobning af 
væske i vævet (ødem) og hjertesygdomme) </li>
<li>kaliumtilskud (anvendes til at forebygge eller behandle lavt kaliumindhold i blodet) </li>
<li>ciclosporin (anvendes til at forebygge eller behandle transplantatafstødning) </li>
<li>heparinnatrium (anvendes til at forhindre eller forsinke blodpropper) </li>
<li>nonsteroide antiinflammatoriske lægemidler (NSAID'er) (anvendes til at mindske feber, 
smerter og betændelsestilstande) </li>
<li>
<p>lægemidler, der kan påvirkes af forstyrrelser i blodets kaliumindhold, f.eks.:</p>
</li>
<li>
<p>digitalisglycosider (såsom digoxin, der anvendes til at behandle hjertesvigt og visse 
hjerterytmeforstyrrelser) </p>
</li>
<li>kortikosteroider (anvendes til at behandle betændelsestilstande) </li>
<li>
<p>alle andre lægemidler, der kan medføre forstyrrelser i hjerterytmen såsom:</p>
</li>
<li>
<p>amiodaron og kinidin (anvendes til at regulere hjerterytmen) </p>
</li>
<li>chlorpromazin (anvendes til at behandle visse psykiske sygdomme) </li>
<li>cisaprid (anvendes til at behandle halsbrand) </li>
<li>sparfloxacin (anvendes til at behandle visse bakterielle infektioner). </li>
</ul>
<p>Visse lægemidler kan påvirkes af øgede pH-værdier i urinen som følge af behandling med Sibnayal. 
Disse kan være:</p>
<ul>
<li>salicylater (anvendes til at behandle smerter og betændelsestilstande — aspirinlignende 
lægemidler) </li>
<li>tetracycliner (anvendes til at behandle visse bakterielle infektioner) </li>
<li>barbiturater (sovemedicin). </li>
</ul>
<p>Brug af Sibnayal sammen med mad, drikke og alkohol </p>
<p>Undlad at blande Sibnayal med varm mad eller varme væsker. 
Drik ikke alkohol, mens du tager Sibnayal. </p>
<p>Graviditet, amning og frugtbarhed </p>
<p>Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. </p>
<p>Trafik- og arbejdssikkerhed </p>
<p>Sibnayal forventes ikke at påvirke din evne til at føre motorkøretøj eller betjene maskiner. </p>
<p>Sibnayal indeholder kalium </p>
<p>Sibnayal 8 mEq indeholder 308 mg kalium pr. brev. Det skal du huske på, hvis du har nedsat 
nyrefunktion eller er på kaliumreduceret diæt. </p>
<p>Sibnayal 24 mEq indeholder 924 mg kalium pr. brev. Det skal du huske på, hvis du har nedsat 
nyrefunktion eller er på kaliumreduceret diæt. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. Sådan skal du tage sibnayal"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Sådan skal du tage sibnayal"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<p>Hvor meget Sibnayal du skal tage, afhænger af din alder og vægt og dit helbred. Lægen vil fortælle dig 
nøjagtigt, hvilken dosis Sibnayal du skal tage. Det vil altid være ét eller flere breve. </p>
<p>Lægen kan være nødt til at justere dosen af Sibnayal. </p>
<p>Dette lægemiddel skal bruges under lægeopsyn. </p>
<p>Dosering </p>
<p>Lægen tilpasser dosis afhængigt af indholdet af bicarbonat i dit blod. </p>
<p>Sådan skal du tage Sibnayal </p>
<p>Sibnayal er til oral anvendelse (dvs. det skal tages gennem munden). 
Hvis du ikke er sikker på, hvordan du skal bruge Sibnayal, skal du kontakte din læge eller dit apotek. </p>
<ol>
<li>
<p>Hold brevet lodret med fingrene over den punkterede linje. Ryst det fra side til side for at sikre, at 
indholdet flyttes til bunden af brevet. </p>
</li>
<li>
<p>Klip brevet langs den punkterede linje. Brug en saks, hvis det er nødvendigt. </p>
</li>
<li>
<p>Anbring hele eller en del af brevets indhold direkte i munden på tungen. </p>
</li>
<li>
<p>Synk straks granulatet med et stort glas vand. Undlad at tygge eller knuse granulatet. Gentag punkt 
1 til 4 efter behov, indtil du har taget den fulde dosis. </p>
</li>
</ol>
<p>Til patienter, der ikke kan synke granulat </p>
<ol>
<li>
<p>Bland Sibnayal med små mængder blød og kold mad (f.eks. frugtmos eller yoghurt) direkte på 
skeen. Du skal synke den bløde blanding straks. Gem ikke blandingen til senere. </p>
</li>
<li>
<p>Anbring blandingen direkte i munden, og synk den uden at tygge den. Sørg for, at du ikke har rester 
af Sibnayal i munden. Gentag punkt 1 og 2 efter behov, indtil du har taget den fulde dosis. </p>
</li>
</ol>
<p>Undlad at blande granulatet med væske, før det tages. </p>
<p>Hvornår Sibnayal skal tages </p>
<p>Tag Sibnayal morgen og aften sammen med et måltid. Der skal gå ca. 12 timer mellem hver dosis for 
at dække hele dagen og natten. </p>
<p>Dosisjustering </p>
<p>Dosisforøgelse/-nedsættelse bør ske gradvist og over nogle få uger. Lægen vil tilpasse dosis efter din 
tilstand. Den normale anbefalede dosis er 4 til 6 hele breve a 24 mEq dagligt. </p>
<p>Tal med din læge, hvis du får bivirkninger, da det kan være nødvendigt at justere dosen af dette 
lægemiddel. </p>
<p>Skift fra et andet alkaliserende lægemiddel </p>
<p>Hvis du skifter fra andre alkaliserende lægemidler til Sibnayal, bør din lægen holde nøje øje med dig i 
overgangsperioden. </p>
<p>Hvis du har taget for meget Sibnayal </p>
<p>Kontakt lægen eller apotekspersonalet, hvis du har taget for meget Sibnayal. 
Du kan have kvalme, behov for at kaste op, og diarré. 
Hvis du har taget en stor mængde Sibnayal, kan du føle dig mat eller få uforklarlige 
muskelspændinger, spasmer (muskelkontraktion), unormale snurrende eller brændende fornemmelser, 
prikken og stikken eller følelsesløshed, sindsforvirring eller unormal hjertefrekvens. </p>
<p>Hvis du har glemt at tage Sibnayal </p>
<p>Tag ikke en dobbeltdosis som erstatning for en glemt dosis. Tag det, så snart du kommer i tanke om 
det. Hvis den næste dosis er mindre end 6 timer senere, bør du dog springe den glemte dosis over. Tag 
ikke mere end to doser dagligt. </p>
<p>Tal med lægen, hvis du har glemt at tage én eller flere doser. </p>
<p>Hvis du holder op med at tage Sibnayal </p>
<p>Dette lægemiddel er beregnet til langtidsbehandling. Det vil kun virke, så længe du tager det. 
Stop ikke, medmindre lægen beder dig om det. Heller ikke selv om du får det bedre. Sygdommen kan 
nemlig forværres. Hvis du ønsker at stoppe med behandlingen, skal du først tale med din læge. </p>
<p>Spørg lægen, hvis der er noget, du er i tvivl om. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Bivirkninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Bivirkninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Meget almindelige bivirkninger (som kan forekomme hos mere end 1 ud af 10 personer) 
- mavesmerter </p>
<p>Almindelige bivirkninger (som kan forekomme hos op til 1 ud af 10 personer) 
- smerter i den øvre del af maven 
- gastrointestinale smerter og sygdomme (smerter og sygdomme i mave-tarm-kanalen) 
- dyspepsi (dårlig fordøjelse), 
- opkastning 
- diarré 
- kvalme, når behandlingen indledes. </p>
<p>Indberetning af bivirkninger </p>
<p>Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også </p>
<p>indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. Opbevaring"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Opbevaring"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på brevet og kartonen efter EXP. Udløbsdatoen er 
den sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 25°C. </p>
<p>Når du har åbnet et brev, skal du kassere eventuelt ikke anvendt indhold. </p>
<p>Af hensyn til miljøet må du ikke smide medicinrester i afløbet, toilettet eller skraldespanden. Spørg 
apotekspersonalet, hvordan du skal bortskaffe medicinrester. Dette vil være med til at skåne miljøet. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Pakningsstørrelser og yderligere oplysninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Pakningsstørrelser og yderligere oplysninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sibnayal indeholder: </p>
<p>De aktive stoffer er kaliumcitrat og kaliumhydrogencarbonat (også kaldet kaliumbicarbonat). </p>
<p>Hvert brev Sibnayal 8 mEq indeholder 282 mg kaliumcitrat og 527 mg kaliumhydrogencarbonat. </p>
<p>Hvert brev Sibnayal 24 mEq indeholder 847 mg kaliumcitrat og 1.582 mg kaliumhydrogencarbonat. </p>
<p>De øvrige indholdsstoffer er hydroxypropylmethylcellulose (E464), mikrokrystallinsk cellulose (E(i)), glyceroldibehenat, magnesiumstearat (E470b), silica, kolloid vandfri, magnesiumoxid, tungt 
(E530), ethylcellulose (E462), chlorophyllin (E140 (ii)), talkum. </p>
<p>Udseende og pakningsstørrelser </p>
<p>Sibnayal er en blanding af grønt og hvidt depotgranulat, der fås i breve. 
Kartonerne indeholder 60 breve. </p>
<p>Sibnayal fås i multipakninger, som består af 2, 3, 4, 5 og 6 kartoner, der hver indeholder 60 breve. 
Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen </p>
<p>ADVICENNE 
262 rue du Faubourg Saint Honoré<br />
75008 Paris 
Frankrig </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien - Luxembourg/Luxemburg - Nederland 
TwinPharma BV 
Trasmolenlaan 5 
Italia 
SPA Società Prodotti Antibiotici S.p.A. 
Tel: +39 02 891 </p>
<p>3447 GZ Woerden 
Nederland 
Tél/Tel: +31 348 71 24 e-mail: info@twinpharma.com </p>
<p>България 
ExCEEd Orphan s.r.o. 
Bucharova 2657/12, Prague 5, 158 Czech republic 
Teл.: +359 888 918 pv.global@exceedorphan.com </p>
<p>Magyarország 
ExCEEd Orphan s.r.o. 
Bucharova 2657/12, Prague 5, 158 Czech republic 
Tel.: +36 20 399 4pv.global@exceedorphan.com 
Česká republika 
ExCEEd Orphan s.r.o. 
Bucharova 2657/12, Prague 5, 158 Czech republic 
Tel: +420 608 076 pv.global@exceedorphan.com </p>
<p>Polska 
ExCEEd Orphan s.r.o. 
Bucharova 2657/12, Prague 5, 158 Czech republic 
Tel.: +48 502 188 pv.global@exceedorphan.com 
Danmark - Norge - Suomi/Finland - Sverige 
Frostpharma AB 
Berga Backe 2 
18253 Danderyd, Sverige<br />
Tlf/Puh/Tel: + 46 8 243regulatory@frostpharma.com </p>
<p>Portugal 
Prospa - Laboratórios Farmacêuticos, S.A. 
Tel: +351 214171 
Deutschland - Eesti - Ελλάδα - France - 
Ireland - Ísland - Κύπρος - Latvija - Lietuva - Malta - Österreich - United Kingdom 
(Northern Ireland) 
ADVICENNE 
262 rue du Faubourg Saint Honoré<br />
75008 Paris, France 
Tel : + 33 1 85 73 36<br />
România 
ExCEEd Orphan s.r.o. 
Bucharova 2657/12, Prague 5, 158 Czech republic 
Tel: +40 744 366 pv.global@exceedorphan.com 
España 
SPA farma Ibérica<br />
Tel: + 34 622 273  </p>
<p>Slovenija 
ExCEEd Orphan s.r.o. 
Bucharova 2657/12, Prague 5, 158 Czech republic 
Tel: +386 30 210 pv.global@exceedorphan.com </p>
<p>Hrvatska 
ExCEEd Orphan Distribution d.o.o. 
Savska cesta 32, Zagreb, 100 Croatia 
Tel: +385 99 320 0pv.global@exceedorphan.com<br />
Slovenská republika 
ExCEEd Orphan s.r.o. 
Bucharova 2657/12, Prague 5, 158 Czech republic 
Tel: +420 608 076 pv.global@exceedorphan.com </p>
<p>Fremstiller </p>
<p>ELAIAPHARM 
2881 route des Crêtes 
ZI les Bouillides Sophia Antipolis 
06560 Valbonne </p>
<p>Frankrig </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. </p> </div>"""      





                    
Instance: bundlepackageleaflet-en-1d09f2cdb23b1c4baeb1be5a4de77a38
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for sibnayal Package Leaflet for language en"
Description: "ePI document Bundle for sibnayal Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-1d09f2cdb23b1c4baeb1be5a4de77a38"
* entry[0].resource = composition-en-1d09f2cdb23b1c4baeb1be5a4de77a38

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp1d09f2cdb23b1c4baeb1be5a4de77a38"
* entry[=].resource = mp1d09f2cdb23b1c4baeb1be5a4de77a38
                            
                    
Instance: bundlepackageleaflet-da-1d09f2cdb23b1c4baeb1be5a4de77a38
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for sibnayal Package Leaflet for language da"
Description: "ePI document Bundle for sibnayal Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-1d09f2cdb23b1c4baeb1be5a4de77a38"
* entry[0].resource = composition-da-1d09f2cdb23b1c4baeb1be5a4de77a38

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp1d09f2cdb23b1c4baeb1be5a4de77a38"
* entry[=].resource = mp1d09f2cdb23b1c4baeb1be5a4de77a38
                            
                    



Instance: mp1d09f2cdb23b1c4baeb1be5a4de77a38
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Sibnayal 8 mEq prolonged-release granules"
Description: "Sibnayal 8 mEq prolonged-release granules"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/20/1517/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Sibnayal 8 mEq prolonged-release granules"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 1d09f2cdb23b1c4baeb1be5a4de77a38ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "sibnayal"

* status = #current
* mode = #working

* title = "List of all ePIs associated with sibnayal"

* subject = Reference(mp1d09f2cdb23b1c4baeb1be5a4de77a38)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#sibnayal "sibnayal"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-1d09f2cdb23b1c4baeb1be5a4de77a38) // sibnayal en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-1d09f2cdb23b1c4baeb1be5a4de77a38) // sibnayal da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-1d09f2cdb23b1c4baeb1be5a4de77a38
InstanceOf: List

* insert 1d09f2cdb23b1c4baeb1be5a4de77a38ListRuleset
    